A Germany-based KOL discusses epidemiology and patient segmentation in ALL, followed by detailed coverage of treatment pathways from diagnosis through relapse across pediatric and adult populations. The discussion also covered use and sequencing of chemotherapy, asparaginase formulations, TKIs for Ph-positive disease, stem cell transplantation, and the roles of blinatumomab and inotuzumab in frontline and relapsed settings. The interview also covers CAR-T therapies, emerging pipeline assets (including T-cell ALL approaches), regulatory considerations, treatment duration, and key unmet needs in ALL management.

This interview was conducted on July 21, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.